DICE Therapeutics
progression to phase in psoriasis dice | DICE Therapeutics
Company
Deck Type
Deck date
March 2023
Slide
47 of 59
Related slides by other companies
23andMe
Investor Day
January 2022
we have generated a research and development pipeline covering multiple therapeutic areas | 23andMe
Ocuphire Pharma
Results
January 2023
clinically meaningful registration in | Ocuphire Pharma
BenevolentAI
Investor Conference
January 2023
ben indicative data from phase caveats phase was not powered to meaningfully assess only patients dosed with active per group maximum duration of dosing days score changes typically measured at days | BenevolentAI
Valneva
IPO
April 2021
phase trial led to direct progression into phase | Valneva
Other recent decks by DICE Therapeutics
See all presentations (4 decks)
Results
March 2023
Investor Presentation
March 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io